Positive Trial Results For Human Genome And GlaxoSmithKline
Human Genome Sciences Inc. (Nasdaq: HGSI) and GlaxoSmithKline (NYSE: GSK) announced positive results for its lupus drug treatment and planned to get FDA approval in 2010. Shares of Human Genome leaped $5.16 to $23.85 while GlaxoSmithKline stock eased 59 cents to $40.57.
